The chapter explores the recent FDA ruling categorizing peptides like BPC 157 and CJC 1295 as category two, prohibiting their sale by compounding pharmacies. It discusses the risks, legal implications, and the ongoing sales of these peptides for research purposes. The conversation delves into the regulatory challenges, safety concerns, and implications for the performance-enhancing industry.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode